ABSTRACT
The Bethesda System (TBS) 2001 introduced Papanicolaou (Pap) test reporting of benign-appearing endometrial cells (nEMCs) in women 40 years and older, 1, 2 replacing earlier TBS 1988 reporting of nEMCs only in postmenopausal women. 3, 4 Shedding of nEMCs in Pap smears of postmenopausal women has long been considered an abnormal finding associated with sufficiently increased risk of endometrial carcinoma [5] [6] [7] such that routine endometrial assessment by either ultrasound or tissue sampling has been recommended. 8, 9 The stated reason for the TBS 2001 reporting change for nEMCs was that "menopausal status is often unclear, inaccurate, or unknown to the laboratory." 10, 11 TBS 2014 slightly further limited reporting of nEMCs to women 45 years and older "to improve the predictive value of exfoliated benign-appearing EMC." 11 Although nEMCs in Pap smears of Upon completion of this activity you will be able to:
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cycling women are a common normal finding, 5, 6 consensus follow-up guidelines after the TBS 2001 reporting change began to refer to nEMCs in Pap smears of women 40 years and older as a "glandular abnormality." 8 The focus of TBS 2014 on the positive predictive value of nEMCs for the presence of underlying endometrial carcinoma also implied that nEMCs in women 40 years or older were an abnormal cytologic finding. As a consequence of these reporting changes, endometrial diagnostic surgical procedures substantially increased, 5, [12] [13] [14] [15] without evidence of clinical benefit for the large subset of women 40 years and older with Pap smear findings of nEMCs and not otherwise candidates for endometrial assessment due to either being postmenopausal 8, 9 or having abnormal uterine bleeding. 16 Since nEMCs in Pap smears of asymptomatic cycling women are overwhelmingly a nonpathologic finding, we concluded that the negative predictive value (NPV) of nEMCs is the more appropriate and relevant measure to consider rather than the positive predictive value. No previous studies have reported the NPV of nEMCs in Pap smears of women 40 years and older against relevant endometrial histopathologic end points. Therefore, we report here the NPV associated with Pap smear findings of nEMCs in women 40 years and older based on an analysis of a large 11-year academic women's hospital database.
Materials and Methods

Case Selection
The study was approved by the Institutional Review Board at the University of Pittsburgh Medical Center (UPMC). The database of electronic medical records consisted of 1,036,629 Pap test reports and 121,079 surgical pathology reports signed out during an 11-year period (January 1, 2005, to December 31, 2015) at Magee-Womens Hospital (MWH) of UPMC. A data search identified cases with Pap test reports of nEMCs in women 40 years and older on days 1 to 12 of the menstrual cycle, nEMCs in women 40 years and older after day 12 of the menstrual cycle, nEMCs in women 40 years and older with unknown menstrual or menopause status, and nEMCs in women 40 years and older designated postmenopausal. Follow-up histopathologic endometrial reports within 6 months were documented. Cases with nEMCs correlating with menstrual history (days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] were excluded since this finding is universally acknowledged by cytopathologists as an unremarkable cytologic finding. 5, 6 Nearly all (>99%) Pap tests performed during the study period were liquid-based ThinPrep Pap tests (Hologic/Cytyc, Marlborough, MA). Follow-up surgical specimens included endometrial biopsy specimens, endometrial curettage specimens, and hysterectomies.
Data Recording
Each patient's age at the time of Pap testing, follow-up histopathologic results, and clinical information were obtained from the electronic medical records at UPMC. For patients undergoing two or more procedures during the 6-month follow-up period, only the most abnormal histopathologic diagnosis was recorded. Endometrial carcinoma (EmCa) and its most common precursor lesion, atypical endometrial hyperplasia (AEH), were chosen as the clinically relevant endometrial histopathologic end points. Patients were stratified into 5-year age groups from 40 to 60 and older.
Statistical Analysis
NPV and number of cases with EmCa/AEH histopathologic or other benign follow-up findings were analyzed. A statistical analysis of the data was performed in STATISTICA (StatSoft, Tulsa, OK). The P values were calculated using a two-sided Fisher exact test.
Bayesian Network Modeling
The Pittsburgh Cervical Cancer Screening Model, constructed and continuously updated with 11 years of the MWH-UPMC electronic database, is a dynamic Bayesian network decision science modeling system that can generate quantitative risk estimates for development of various gynecologic malignancies over time in patients with differing clinical histories, prior screening test results, and prior surgical pathology results. 17, 18 A Structural Modeling, Inference, and Learning Engine (SMILE) and GeNIe, a development environment for reasoning in graphical probabilistic models, were employed. Both SMILE and GeNIe were developed in the Decision Systems Laboratory of the University of Pittsburgh School of Information Sciences and are available at http://www.bayesfusion.com. We used our database to build a Bayesian network model to estimate the likelihood of follow-up histopathologic diagnoses of EmCa/AEH vs other benign histopathologic endometrial findings in women 40 years and older with prior Pap test results of nEMCs. The model included other variables such as patient age and clinical history data such as postmenopausal status and bleeding. The Bayesian network model allowed us to generate quantitative relative risk projections for AEH or EmCa.
Results
Searching the 11-year UPMC database identified a total of 17,859 cases with Pap test reports of nEMCs in women 40 years and older. A total of 8,213 cases with nEMCs correlating with menstrual history (days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] were excluded from our NPV study; nevertheless, 900 (11.0%) of these 8,213 patients had documented endometrial tissue sampling within 6 months. The remaining 9,646 cases, which were the focus of this NPV study, included 8,583 reporting nEMCs in women 40 years and older after day 12 of the menstrual cycle or with no documented last menstrual period (LMP) and 1,063 reporting nEMC in patients designated as postmenopausal. Endometrial tissue sampling within 6 months of Pap test reports of nEMCs in these women 40 years and older was documented in 2,803 (32.7%) of 8,583 patients with nEMCs after day 12 or no LMP and in 528 (49.7%) of 1,063 patients designated as postmenopausal.
The 3,331 patients 40 years and older with nEMC Pap reports and subsequent endometrial (EM) sampling within 6 months were stratified into 5-year age groups and analyzed for benign vs neoplastic (EmCa/AEH) endometrial histopathologic diagnoses and related NPVs ❚Table 1❚ and ❚Table 2❚. EmCa or AEH was diagnosed in 1% or less of patients aged 40 to 44 years and 45 to 49 years (0.48% and 0.74%, respectively). There was no statistically significant difference in NPV between these two groups of patients aged 40 to 44 years and 45 to 49 years (99.5% and 99.3%, respectively). In contrast, a significant decrease in NPV was detected in patient groups 50 years and older (97.1%, 95.3%, and 94.5%, respectively) compared with patients aged 40 to 49 years (P from .001 to <.00001). No statistically significant difference in NPV was noted between 5-year age subgroups of women aged 50 to 60 years or 60 years and older. Therefore, patients younger than 50 years and 50 years and older represent two statistically different risk groups for neoplastic endometrial histopathologic outcomes in patients 40 years and older with nEMC Pap test results.
Further analysis of clinical findings documented in the electronic medical records of patients with neoplastic (EmCa/AEH) follow-up EM diagnoses revealed that, among 1,869 women aged 40 to 49 years, only two (0.1%) asymptomatic patients had follow-up histopathologic diagnoses of AEH or superficial low-grade EmCa. All other patients younger than 50 years with EmCa/AEH follow-up diagnoses had abnormal clinical findings, including abnormal vaginal bleeding, menorrhagia, or EM thickening (one case) at the time the Pap test with nEMCs was collected.
Taking into account patient age and clinical history data, Bayesian modeling was employed to estimate quantitative risk for EmCa/AEH in patients 40 years and older with nEMC Pap test reports. Quantitative risk projections varied according to patient age groups and clinical symptoms ❚Figure 1❚. Patients in all age groups without bleeding history had negligible or very low risk for subsequent EmCa/AEH compared with patients with abnormal bleeding. Patients without bleeding history who were 50 years and older did have slightly higher risk estimates compared with patients 50 years and younger. In all age groups, patients with clinical findings of abnormal bleeding had a much higher risk for EmCa/AEH compared with patients without bleeding history, with markedly increased risk projected for patients 50 years and older.
Discussion
The health care system is under increasing pressure to deliver value and reduce waste. 19 TBS reporting of nEMCs in women 40 years and older and more recently in women 45 years and older provides an unfortunate example of a standardized reporting format that has inadvertently resulted in widespread unnecessary diagnostic endometrial sampling of asymptomatic cycling women without delivering measurable clinical value. 5, [12] [13] [14] [15] The primary reason for this failure appears to be the common misunderstanding that nEMCs reported in Pap smears of cycling women represent a cytologic abnormality. This misunderstanding became evident after TBS 2001 as endometrial sampling significantly increased in premenopausal 
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8 TBS 2014 appears to have further compounded this misunderstanding by focusing on "predictive values" (positive predictive values) for this normal (negative) cytologic finding without further age stratifications. 11 Our current study is the first to focus on the more appropriate metric of NPV. The NPV for nEMCs was 99.5% in women aged 40 to 44 years and 99.3% in women aged 45 to 49 years (Table 1) . There was no statistically significant difference in NPV between these two groups of patients. NPVs began to decrease slightly in women 50 years and older (Table 1) . Furthermore, Bayesian modeling of our data set documented that risk for histopathologic diagnoses of EmCa/ AEH in women 40 years and older with nEMCs reported on their Pap smears is best predicted by bleeding (not otherwise specified) history or postmenopausal bleeding history, especially in women 50 years and older (Figure 1 ). These findings support the observations of numerous investigators that nEMCs in Pap smears of women 40 years and older resulted in increased reporting only in premenopausal women and endometrial biopsy specimens that rarely documented significant pathology. 5, 6, [9] [10] [11] [12] [13] [14] [15] Although current follow-up guidelines 9 recommend no further evaluation for asymptomatic premenopausal women with nEMCs reported on their Pap smears, consensus guideline recommendations are often not followed. 20 Adding an educational note to the Pap test report may help reduce some unnecessary endometrial biopsies. 21 A specific recommendation we have begun to include on Pap test reports of nEMCs in women 45 years and older is as follows: routine periodic screening is recommended for asymptomatic premenopausal women 45 years and older with benign-appearing endometrial cells on their Pap tests 9 ; please confirm that this patient is neither postmenopausal nor having abnormal uterine bleeding. Some time ago, we also instituted the practice of explicitly reporting nEMCs in patients known to be postmenopausal as an epithelial cell abnormality. These cases are reported as follows: "Interpretation-Endometrial Cells in a Post-menopausal Woman. Negative for Squamous Intraepithelial Lesion. Recommendation-Endometrial tissue sampling or ultrasound assessment is suggested." 9 This approach emphasizes that current clinical follow-up guidelines recommend follow-up specifically for this subset of patients with Pap test findings of nEMCs. This approach is similar to TBS 1988.
Nevertheless, the common misunderstanding remains that shedding of nEMCs in Pap tests is an abnormal finding, both among clinicians and among pathologists. Even though Pap test results have never been shown to have a significant survival benefit for endometrial cancer cases diagnosed in a screened population, 22 identification of atypical glandular cells on Pap tests may lead to some diagnoses of endometrial cancers. 23 When we queried the authors of the TBS 2014 section titled "Endometrial Cells: The How and When of Reporting," we were specifically advised that "benign-appearing endometrial cells have traditionally been considered an abnormal finding because of their association with endometrial neoplasia" (personal communication with Edmund S. Cibas, MD, et al, by R.M.A., October 13, 2015). We believe this misunderstanding needs ❚Figure 1❚ Relative risk projections for histopathologic diagnoses of atypical endometrial hyperplasia or endometrial carcinoma within 6 months of Papanicolaou (Pap) test reports of benign-appearing endometrial cells present in Pap tests of women 40 years and older who had no history of bleeding or had a history of postmenopausal bleeding or bleeding not otherwise specified.
to be recognized. Data presented in this study confirm that even nEMCs shed after day 12 in Pap tests are overwhelmingly a normal (negative) cytologic finding associated with high NPV for the presence of underlying EmCa or AEH. Another large study from our institution documented that endometrial sampling provided virtually no clinical benefit in premenopausal women younger than 50 years whose Pap smears showed nEMCs after day 12. 24 Review of the literature confirms that even nEMCs shed in the second half of the cycle are unlikely to be associated with significant pathology in the absence of other clinical findings independently warranting investigation. 6 Resolution of the problem of unnecessary endometrial biopsies triggered by TBS 2001 and TBS 2014 reporting changes for findings of nEMCs in Pap smears of premenopausal women is challenging. Relevant clinical information that could point independently to the need for endometrial assessment is often not included on Pap test requisition forms. Despite this limitation, the high NPVs we have documented when nEMCs were reported on Pap smears of women in their 40s clearly suggest that the harms associated with unnecessary procedurization outweigh any still-unproven benefits. NPVs associated with Pap smear findings of nEMCs in women without bleeding histories remain very high, even for women in their 50s and 60s, further suggesting that even for these patients, the primary emphasis should focus on other clinical findings, especially abnormal uterine bleeding. 16 A possible limitation of this study is that the data were from a single institution's experience, which could theoretically reflect geographic selection bias. In an ideal world, multicenter prospective studies would be useful to corroborate the findings. Nevertheless, our data, which covered more than a decade and nearly 10,000 study cases, confirm observations made as far back as 1999 that the presence of normal endometrial cells in Pap smears has very limited significance and may primarily create a management dilemma for clinicans. 25 TBS reporting of nEMCs in women 40 years and older has been misunderstood as an abnormal cytologic finding associated with significant positive predictive value for endometrial neoplasia, a misunderstanding that has led to many unproductive endometrial procedures, despite an absence of proven clinical benefit. Even Pap smear findings of nEMCs during the second half of the menstrual cycle are associated with very high NPVs for the absence of either EmCa or AEH. These observations need to be more widely discussed among multiple specialty disciplines to reduce the widespread unnecessary endometrial biopsies caused by routine reporting of nEMCs in Pap smears of premenopausal women. Both clinicians and pathologists need to pay more attention to the significance of relevant clinical modifiers (abnormal uterine bleeding and postmenopausal status) in determining optimal follow-up of patients with nEMCs on their Pap tests.
